Drugs / LL37
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02225366 | Jul 2015 → Nov 2020 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04098562 | Oct → Dec 2019 | ulcer of lower limbs | Faculty of Medicine, University of Indonesia | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LL-37 | “LL-37 has antimicrobial property, induces angiogenesis, and keratinocyte migration and proliferation.” PMID 37480520 ↗ Jul 2023 |
| Modality | Peptide | “Antimicrobial peptide LL37” NCT02225366 ↗ |
| Route | Other | “LL37 administered intratumorally in cutaneous or subcutaneous tumors” NCT02225366 ↗ |